CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
54.26
+0.74 (1.38%)
Aug 10, 2026, 10:45 AM EDT - Market open
CRISPR Therapeutics AG Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 13.39 | 3.51 | 37.31 | 371.21 | 1.2 | 914.96 |
Revenue Growth | -64.80% | -90.59% | -89.95% | 30885.48% | -99.87% | 127154.94% |
Gross Profit Gross Profit Growth | 13.39 | 3.51 | 37.31 | 371.21 | 1.2 | 914.96 |
Operating Income Operating Income Growth | -534.34 | -664.57 | -466.57 | -222.54 | -673.16 | 373.53 |
Net Income Net Income Growth | -451.14 | -581.6 | -366.25 | -153.61 | -650.18 | 377.66 |
Earnings Per Share EPS Growth | -4.76 | -6.47 | -4.34 | -1.94 | -8.36 | 4.70 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Collaboration Collaboration Growth | - | - | 35 | 370 | 0.44 | 913.08 |
Grant Grant Growth | 2.39 | 3.51 | 2.31 | 1.21 | 0.76 | 1.88 |
Revenue (Total) Revenue (Total) Growth | 13.39 | 3.51 | 37.31 | 371.21 | 1.2 | 914.96 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 2,364 | 1,976 | 1,904 | 1,694 | 1,815 | 2,379 |
Total Debt Total Debt Growth | 783.75 | 206.75 | 223.69 | 238.63 | 244.02 | 225.03 |
Net Cash (Debt) Net Cash Growth | 1,581 | 1,769 | 1,680 | 1,455 | 1,571 | 2,154 |
Net Cash Growth | 4.97% | 5.29% | 15.47% | -7.40% | -27.05% | 32.24% |
Net Cash Per Share Net Cash Per Share Growth | 16.68 | 19.67 | 19.92 | 18.37 | 20.21 | 26.79 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -369.58 | -345.01 | -142.77 | -260.38 | -495.74 | 538.97 |
Capital Expenditures CapEx Growth | -1.74 | -0.91 | -1.9 | -9.47 | -37.19 | -81.71 |
Free Cash Flow Free Cash Flow Growth | -371.33 | -345.93 | -144.68 | -269.85 | -532.93 | 457.27 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -3989.99% | -18933.60% | -1250.38% | -59.95% | -56190.40% | 40.82% |
Pretax Margin | -3346.08% | -16466.24% | -971.93% | -40.60% | -54298.83% | 41.48% |
Profit Margin | -3368.72% | -16569.80% | -981.54% | -41.38% | -54271.70% | 41.28% |
FCF Margin | -2772.74% | -9855.50% | -387.72% | -72.69% | -44484.90% | 49.98% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 16.12 |
P/FCF Ratio | - | - | - | - | - | 12.76 |
PS Ratio | 386.42 | 1432.68 | 90.44 | 13.50 | 2664.05 | 6.38 |